Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1991 | 1 |
| 1994 | 1 |
| 2000 | 1 |
| 2002 | 3 |
| 2003 | 4 |
| 2004 | 8 |
| 2005 | 18 |
| 2006 | 24 |
| 2007 | 35 |
| 2008 | 49 |
| 2009 | 58 |
| 2010 | 69 |
| 2011 | 95 |
| 2012 | 132 |
| 2013 | 189 |
| 2014 | 170 |
| 2015 | 202 |
| 2016 | 189 |
| 2017 | 206 |
| 2018 | 244 |
| 2019 | 265 |
| 2020 | 341 |
| 2021 | 389 |
| 2022 | 426 |
| 2023 | 400 |
| 2024 | 323 |
| 2025 | 318 |
| 2026 | 176 |
Search Results
3,803 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Predictive Role of Neutrophil-Percentage-to-Albumin Ratio (NPAR) in Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Nondiabetic US Adults: Evidence from NHANES 2017-2018.
Nutrients. 2023 Apr 14;15(8):1892. doi: 10.3390/nu15081892.
Nutrients. 2023.
PMID: 37111111
Free PMC article.
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent globally and includes chronic liver diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). ...The NPAR may serve as a biomarker for NAFL …
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent globally and includes chronic liver d …
Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Diabetes Metab Syndr. 2023 Oct;17(10):102849. doi: 10.1016/j.dsx.2023.102849. Epub 2023 Sep 13.
Diabetes Metab Syndr. 2023.
PMID: 37717295
AIM: This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis …
AIM: This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in pati …
Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis.
Ann Hepatol. 2024 Mar-Apr;29(2):101174. doi: 10.1016/j.aohep.2023.101174. Epub 2023 Oct 29.
Ann Hepatol. 2024.
PMID: 38579127
Free article.
INTRODUCTION AND OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with a high prevalence worldwide and poses serious harm to human health. ...The levels of fatty liver index (SMD[95%CI]= …
INTRODUCTION AND OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver diseas …
FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
BMC Gastroenterol. 2021 Dec 3;21(1):453. doi: 10.1186/s12876-021-02038-3.
BMC Gastroenterol. 2021.
PMID: 34861841
Free PMC article.
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. ...METHODS: This cross-sectional study included patients with NAFLD or non-alcoholic steatohepati …
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver d …
Formononetin promotes fatty acid beta-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1alpha/PPARalpha pathway.
Phytomedicine. 2024 Feb;124:155285. doi: 10.1016/j.phymed.2023.155285. Epub 2023 Dec 16.
Phytomedicine. 2024.
PMID: 38185065
BACKGROUND: Non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD), carries a high risk of cirrhosis and hepatocellular carcinoma. ...RESULTS: Our study found that afte …
BACKGROUND: Non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty l …
Nonalcoholic fatty liver disease.
Pediatr Rev. 2015 May;36(5):198-205; quiz 206. doi: 10.1542/pir.36-5-198.
Pediatr Rev. 2015.
PMID: 25934909
Free article.
Review.
On the basis of strong research and consensus, nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in children and is soon to be the most common indication for liver transplantation in adults. ...The di …
On the basis of strong research and consensus, nonalcoholic fatty liver disease (NAFLD) is the most commo …
Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis.
Int J Mol Sci. 2023 May 23;24(11):9168. doi: 10.3390/ijms24119168.
Int J Mol Sci. 2023.
PMID: 37298120
Free PMC article.
Nonalcoholic fatty liver disease (NAFLD) has emerged as a global health problem that affects people even at young ages due to unhealthy lifestyles. Without intervention, NAFLD will develop into nonalcoholic steatohepatitis (NASH …
Nonalcoholic fatty liver disease (NAFLD) has emerged as a global health problem that affects people even …
ALT poorly predicts Nonalcoholic Fatty Liver Disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult National Health and Nutrition Examination Survey 2017-2018.
Am J Med Sci. 2024 May;367(5):310-322. doi: 10.1016/j.amjms.2024.01.022. Epub 2024 Feb 1.
Am J Med Sci. 2024.
PMID: 38307172
Free PMC article.
BACKGROUND: Non-alcoholic fatty liver disease is a growing problem in the United States, contributing to a range of liver disease as well as cardiovascular disease. ...RESULTS: Based on three of the most widely used cut off …
BACKGROUND: Non-alcoholic fatty liver disease is a growing problem in the United States, contributing to …
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.
Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18.
Adv Exp Med Biol. 2024.
PMID: 39287864
Review.
Nonalcoholic fatty liver disease (NAFLD) is in parallel with the obesity epidemic, and it is the most common cause of liver diseases. ...Lipotoxicity-related mechanism of NAFLD could be explained still best by the "double-hit" hypo …
Nonalcoholic fatty liver disease (NAFLD) is in parallel with the obesity epidemic, and it is the most com …
Non-Alcoholic Fatty Liver Disease.
Adv Exp Med Biol. 2017;960:443-467. doi: 10.1007/978-3-319-48382-5_19.
Adv Exp Med Biol. 2017.
PMID: 28585211
Free article.
Review.
Non-alcoholic fatty liver disease (NAFLD) is in parallel with the obesity epidemic and it is the most common cause of liver diseases. ...Insulin resistance is the major mechanism in the development and progression of NAFLD/ …
Non-alcoholic fatty liver disease (NAFLD) is in parallel with the obesity epidemic and it is the m …
Cite